The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
WEGOVY
Date registered
Evaluation commenced
Decision date
Approval time
190 (255 working days)
Active ingredients
Semaglutide
Registration type
EOI
Indication
Wegovy is now also indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:
- obesity* and
- body weight above 60 kg
Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.